Walgreens, KFF partner for largest-ever National HIV Testing Day

Published 12/06/2025, 14:10
Walgreens, KFF partner for largest-ever National HIV Testing Day

DEERFIELD, Ill. & SAN FRANCISCO - Walgreens and KFF’s Greater Than HIV/STDs campaign will offer free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for National HIV Testing Day.

The initiative involves over 415 local health departments and community organizations across nearly all states, Washington, D.C., and Puerto Rico, marking the largest participation in the partnership’s 15-year history. Since 2011, the collaboration has provided more than 93,000 free HIV/STD tests. With investors’ attention on healthcare initiatives, InvestingPro subscribers can access exclusive insights and detailed analysis through the comprehensive Pro Research Report, available for Walgreens and 1,400+ other top stocks.

"This year’s record-breaking National HIV Testing Day activation shows the power of public-private partnership," said Tina Hoff, KFF Senior Vice President.

Testing will be conducted in private areas of stores or mobile units by trained counselors, with results available within 20 minutes. Information about prevention methods, including PrEP and doxy-PEP, will also be provided.

The expanded testing offerings come amid ongoing high rates of syphilis and other STDs in the U.S. Leading manufacturers have donated more than 22,000 rapid test kits to support the event.

Rick Gates, chief pharmacy officer at Walgreens, noted that all Walgreens pharmacists receive HIV prevention training, with approximately 3,000 specialty and community pharmacists completing advanced training in HIV treatment and prevention.

The initiative is further supported by national health organizations including the Association of State and Territorial Health Officials and the National Association of County and City Health Officials.

Walgreens (NASDAQ:WBA) operates approximately 8,500 stores throughout the U.S. and Puerto Rico, offering investors an attractive 8.82% dividend yield. The company is scheduled to report its next earnings on June 26, which InvestingPro subscribers can analyze using advanced financial metrics and expert insights. The information in this article is based on a press release statement.

In other recent news, Walgreens Boots Alliance, Inc. has made significant financial and legal moves. The company has terminated two major credit agreements and launched a new accounts receivable securitization facility with a capacity of up to $2.5 billion. This new facility was created to repay existing debts under previous term loan agreements with Bank of America and Toronto Dominion. Additionally, Walgreens has settled a major legal dispute with the Department of Justice concerning allegations related to opioid dispensing. The settlement involves a payment of $300 million plus interest over six years, with an initial payment of $20 million due soon. As part of the agreement, Walgreens does not admit wrongdoing, and all claims against the company and the DEA will be dismissed. These developments mark the resolution of significant financial and legal challenges for Walgreens.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.